华邦健康(002004) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was CNY 3,399,143,349.29, representing a 20.56% increase compared to CNY 2,819,567,735.13 in the same period last year[5] - Net profit attributable to shareholders for Q1 2022 was CNY 168,625,663.08, up 38.67% from CNY 121,602,831.86 in the previous year[5] - Basic earnings per share for Q1 2022 were CNY 0.0852, reflecting a 38.76% increase from CNY 0.0614 in the same quarter last year[5] - Operating profit for the quarter was ¥479,840,467.75, up 102.5% from ¥236,783,268.06 year-over-year[28] - Net profit attributable to the parent company was ¥168,625,663.08, representing a 38.7% increase from ¥121,602,831.86 in the previous year[32] - The company reported a total comprehensive income of ¥356,932,995.27, compared to ¥175,227,007.48 in the same quarter last year, reflecting a significant growth[32] Cash Flow - The net cash flow from operating activities reached CNY 160,139,339.82, a significant increase of 523.60% compared to a negative cash flow of CNY -37,804,090.99 in Q1 2021[5] - The company reported a net cash flow from investing activities of CNY 26,581,512.40, a 132.48% increase compared to a negative cash flow of CNY -81,838,786.30 in the same period last year[12] - The net cash flow from financing activities was CNY -143,352,411.67, a decrease of 385.88% compared to CNY 50,143,727.51 in Q1 2021, primarily due to increased dividend payments[12] - Cash flow from operating activities amounted to ¥3,158,826,074.20, an increase from ¥2,233,972,460.60 in the previous year[33] - Cash received from operating activities totaled ¥3,392,521,792.08, up from ¥2,397,775,111.68, indicating strong operational performance[36] - Cash paid for goods and services was ¥1,985,219,557.72, an increase from ¥1,239,331,951.48, reflecting higher operational costs[36] Assets and Liabilities - Total assets at the end of Q1 2022 amounted to CNY 30,249,226,747.65, a slight increase of 0.68% from CNY 30,044,426,750.47 at the end of the previous year[5] - The total liabilities decreased by 42.88% in contract liabilities, amounting to CNY 218,861,740.26, down from CNY 383,173,729.03 at the end of the previous year[9] - The total current assets are approximately RMB 12.37 billion, slightly up from RMB 12.31 billion at the beginning of the year[20] - The total assets of the company stand at approximately RMB 30.25 billion, compared to RMB 30.04 billion at the beginning of the year[20] - The total liabilities decreased slightly to ¥14,100,637,646.86 from ¥14,220,677,628.50 year-over-year[24] - Total equity increased to ¥16,148,589,100.79 from ¥15,823,749,121.97, indicating a growth in shareholder value[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 101,127[13] - The largest shareholder, Tibet Huibang Technology Co., Ltd., holds 18.71% of shares, totaling 370,449,804 shares[13] - The company has a total of 184,050,000 shares pledged by the largest shareholder[13] Investment and Expenses - The company's investment income for Q1 2022 was CNY 95,932,564.71, a substantial increase of 387.03% compared to CNY 19,697,316.47 in Q1 2021[9] - Research and development expenses were reported at ¥94,978,374.93, down from ¥101,806,073.76 in the previous year, suggesting a focus on cost management[28] - Cash received from investment income was ¥30,399,478.03, up from ¥19,265,551.30, showing improved returns on investments[36] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[30]